This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2019
A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
Journal of medicinal chemistry · 2006
Latest funding
- $1,262,250
Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements
CIHR · 2026 · Nominated PI
- $891,226
L'AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1
CIHR · 2021 · Nominated PI
- $175,000
Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site
NSERC · 2016 · Principal investigator
2 publications.
Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.
Couillard-Montminy V, Gagnon PY, Fortin S, Côté J
A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
Labrie P, Maddaford SP, Fortin S, Rakhit S, Kotra LP, Gaudreault RC
Développement translationnel de l'AIMZ-938 comme thérapie de précision pour les cancers colorectaux réfractaires aux traitements
Principal investigators: Fortin, Sébastien; Benoit-Biancamano, Marie-Odile; C.-Gaudreault, René; Diorio, Caroline; Droit, Arnaud; Durocher, Francine; Moreau, Emmanuel; Simard, Chantale
Keywords: Antimitotiques; Cancers Colorectaux; Cancers Colorectaux Métastatiques Et Chimiorésistants; Chimiothérapie Personnalisée; Développement De Médicaments Anticancéreux; Modulateurs D'Ahr; Promédicaments Antimicrotubules
L'AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1
Principal investigators: Fortin, Sébastien
Keywords: Antimitotiques; Cancers Du Sein; Cancers Du Sein Chimiorésistants; Cancers Du Sein Triple Négatifs; Chimiothérapie Personnalisée; Développement De Médicaments Anticancéreux; Promédicaments Antimicrotubules
Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site
Principal investigators: Fortin, Sébastien
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.